| 1. Isolated tumor cells and micrometastases in regional lymph nodes in stage I to II endometrial cancer. |
Page:e1— |
| 2. A human papillomavirus (HPV)-16 or HPV-18 genotype is a reliable predictor of residual disease in a subsequent hysterectomy following a loop electrosurgical excision procedure for cervical intraepithelial neoplasia 3. |
Page:e2— |
| 3. Posttreatment human papillomavirus testing for residual or recurrent high-grade cervical intraepithelial neoplasia: a pooled analysis. |
Page:e3— |
| 4. The risk of lymphedema after postoperative radiation therapy in endometrial cancer. |
Page:e4— |
| 5. Incidence of epithelial ovarian cancer according to histologic subtypes in Korea, 1999 to 2012. |
Page:e5— |
| 6. Repair of diaphragmatic injury and placement of tube thoracostomy during right upper quadrant peritonectomy. |
Page:e6— |
| 7. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients. |
Page:e7— |
| 8. Therapeutic options for management of endometrial hyperplasia. |
Page:e8— |
| 9. The role of human papillomavirus testing after treatment for high-grade cervical dysplasia. |
Page:e9— |
| 10. ASGO's Fourth Biennial Meeting, November 12th to 14th, 2015. |
Page:e10— |
| 11. Sentinel lymph node detection in endometrial cancer: hysteroscopic peritumoral versus cervical injection. |
Page:e11— |
| 12. Measuring tumor metabolic heterogeneity on positron emission tomography: utility in cervical cancer. |
Page:e12— |
| 13. Combined modality therapy in the adjuvant treatment of uterine serous carcinoma. |
Page:e13— |
| 14. DNA methylation in human papillomavirus-infected cervical cells is elevated in high-grade squamous intraepithelial lesions and cancer. |
Page:e14— |
| 15. Prognostic value of preoperative intratumoral FDG uptake heterogeneity in early stage uterine cervical cancer. |
Page:e15— |
| 16. Details of recurrence sites after definitive radiation therapy for cervical cancer. |
Page:e16— |
| 17. Definitive treatment of primary vaginal cancer with radiotherapy: multi-institutional retrospective study of the Korean Radiation Oncology Group (KROG 12-09). |
Page:e17— |
| 18. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study. |
Page:e18— |
| 19. The impact of combined radiation and chemotherapy on outcome in uterine papillary serous carcinoma compared to chemotherapy alone. |
Page:e19— |
| 20. Outcomes of laparoscopic fertility-sparing surgery in clinically early-stage epithelial ovarian cancer. |
Page:e20— |
| 21. Clinical significance of human papillomavirus genotyping. |
Page:e21— |
| 22. Toward precision medicine for preserving fertility in cancer patients: existing and emerging fertility preservation options for women. |
Page:e22— |
| 23. Sentinel lymph node detection in endometrial cancer: does injection site make a difference?. |
Page:e23— |
| 24. Major clinical research advances in gynecologic cancer in 2015. |
Page:e53— |
| 25. A prediction model of survival for patients with bone metastasis from uterine cervical cancer. |
Page:e55— |
| 26. Can human papillomavirus (HPV) genotyping classify non-16/18 high-risk HPV infection by risk stratification?. |
Page:e56— |
| 27. Groin lymph node detection and sentinel lymph node biopsy in vulvar cancer. |
Page:e57— |
| 28. Clinical significance of radiotherapy in patients with primary uterine carcinosarcoma: a multicenter retrospective study (KROG 13-08). |
Page:e58— |
| 29. Carcinoma of the cervix in elderly patients treated with radiotherapy: patterns of care and treatment outcomes. |
Page:e59— |
| 30. Surgical therapy of vulvar cancer: how to choose the correct reconstruction?. |
Page:e60— |
| 31. Protective and therapeutic effects of metformin on gynecologic cancers. |
Page:e61— |
| 32. Distal pancreatectomy with splenectomy for the management of splenic hilum metastasis in cytoreductive surgery of epithelial ovarian cancer. |
Page:e62— |
| 33. The 5th Shanghai Gynecologic Oncology Group (SGOG)-Korean Gynecologic Oncology Group (KGOG) joint meeting and 2016 Asia-Pacific Ovarian cancer Laparotomy and Laparoscopic Operation (APOLLO) symposium in Shanghai. |
Page:e64— |
| 34. The epidemiologic status of gynecologic cancer in Thailand. |
Page:e65— |
| 35. Current status of brachytherapy in Korea: a national survey of radiation oncologists. |
Page:e33— |
| 36. Current status of brachytherapy in Korea: a national survey of radiation oncologists. |
Page:e33— |
| 37. Position statements on genetic test for peritoneal, ovarian, and fallopian tubal cancers: Korean Society of Gynecologic Oncology (KSGO). |
Page:e36— |
| 38. Position statements on genetic test for peritoneal, ovarian, and fallopian tubal cancers: Korean Society of Gynecologic Oncology (KSGO). |
Page:e36— |
| 39. Morcellation of apparent benign uterine myoma: assessing risk to benefit ratio. |
Page:e37— |
| 40. Morcellation of apparent benign uterine myoma: assessing risk to benefit ratio. |
Page:e37— |
| 41. Long-term outcomes of magnetic resonance imaging-invisible endometrial cancer. |
Page:e38— |
| 42. Long-term outcomes of magnetic resonance imaging-invisible endometrial cancer. |
Page:e38— |
| 43. Robotic single site versus robotic multiport hysterectomy in early endometrial cancer: a case control study. |
Page:e39— |
| 44. Robotic single site versus robotic multiport hysterectomy in early endometrial cancer: a case control study. |
Page:e39— |
| 45. Extrafascial hysterectomy after concurrent chemoradiotherapy in locally advanced cervical adenocarcinoma. |
Page:e40— |
| 46. Extrafascial hysterectomy after concurrent chemoradiotherapy in locally advanced cervical adenocarcinoma. |
Page:e40— |
| 47. Ovarian cancer screening in menopausal females with a family history of breast or ovarian cancer. |
Page:e41— |
| 48. Ovarian cancer screening in menopausal females with a family history of breast or ovarian cancer. |
Page:e41— |
| 49. Incidence of metastasis in circumflex iliac nodes distal to the external iliac nodes in cervical cancer. |
Page:e42— |
| 50. Incidence of metastasis in circumflex iliac nodes distal to the external iliac nodes in cervical cancer. |
Page:e42— |
| 51. Advances in diagnosis and treatment of metastatic cervical cancer. |
Page:e43— |
| 52. Advances in diagnosis and treatment of metastatic cervical cancer. |
Page:e43— |
| 53. Risk factor analysis for massive lymphatic ascites after laparoscopic retroperitonal lymphadenectomy in gynecologic cancers and treatment using intranodal lymphangiography with glue embolization. |
Page:e44— |
| 54. Risk factor analysis for massive lymphatic ascites after laparoscopic retroperitonal lymphadenectomy in gynecologic cancers and treatment using intranodal lymphangiography with glue embolization. |
Page:e44— |
| 55. Tailored therapy and long-term surveillance of malignant germ cell tumors in the female genital system: 10-year experience. |
Page:e26— |
| 56. Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan. |
Page:e29— |
| 57. Feasibility of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer. |
Page:e24— |
| 58. Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial. |
Page:e25— |
| 59. Time-lapse imaging of sentinel lymph node using indocyanine green with near-infrared fluorescence imaging in early endometrial cancer. |
Page:e27— |
| 60. Impact of diabetes mellitus on oncological outcomes after radical hysterectomy for early stage cervical cancer. |
Page:e28— |
| 61. Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology Guideline. |
Page:e30— |
| 62. Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives. |
Page:e31— |
| 63. Single-port laparoscopic transperitoneal infrarenal para-aortic lymphadenectomy as part of staging operation for early ovarian cancer and high grade endometrial cancer. |
Page:e32— |
| 64. Embryos need a cozy house. |
Page:e34— |
| 65. Ovary is necessary to the health of uterus. |
Page:e35— |
| 66. Impact on survival with adjuvant radiotherapy for clear cell, mucinous, and endometriod ovarian cancer: the SEER experience from 2004 to 2011. |
Page:e45— |
| 67. Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer. |
Page:e46— |
| 68. Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers. |
Page:e47— |
| 69. Clinical outcomes of stage I endometrial carcinoma patients treated with surgery alone: Siriraj Hospital experiences. |
Page:e48— |
| 70. Associations between sexually transmitted infections, high-risk human papillomavirus infection, and abnormal cervical Pap smear results in OB/GYN outpatients. |
Page:e49— |
| 71. The 15th Chinese Society of Gynecologic Oncology National Conference and the 6th Southern China Ovarian Cancer Summit, March 10-13, 2016, Guangzhou. |
Page:e50— |
| 72. Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research. |
Page:e51— |
| 73. Neoadjuvant chemotherapy followed by surgery has no therapeutic advantages over concurrent chemoradiotherapy in International Federation of Gynecology and Obstetrics stage IB-IIB cervical cancer. |
Page:e52— |
| 74. Identification of appropriate cone length to avoid positive cone margin in high grade cervical intraepithelial neoplasia. |
Page:e54— |
